Genomic Health Stock Slides 5 Percent After Analyst Cites Regulatory Concern | GenomeWeb
NEW YORK (GenomeWeb News) — Share in Genomic Health were down 4.85 percent, or $1.15, at $22.57,  in mid-afternoon trading today after Lehman Brothers cut the company’s market rating to ‘equal weight’ from ‘overweight.’
 
According to Reuters, an analyst at the investment bank said he expects the company’s share price to fall if the US Food and Drug Administration enacts regulations that would make it more difficult for the company to sell its Oncotype Dx test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.